Drug Price Transparency

Apr 18, 2023
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter, according to a report released by Turquoise Health.
Apr 18, 2023
It’s no secret that billionaire Mark Cuban has his mind and assets focused on disrupting drug pricing in the U.S. But during a recent talk, Cuban shared new information about what his Cost Plus Drugs company is doing with payers and pharmacists.
Feb 15, 2023
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced yesterday.
Feb 14, 2023
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and…
Nov 2, 2021
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.
Jul 14, 2021
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.
Jul 6, 2021
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304). 
Sep 14, 2020
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.
Oct 9, 2019
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs.